Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

Anne Wojcicki, co-founder and former CEO of 23andMe, will regain control of the embattled genetic testing company through a ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of ...

Regeneron Pharmaceuticals had previously agreed to acquire the company for $256 million. TTAM’s higher bid and added consumer ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...

Regeneron's acquisition of 23andMe raises concerns about data privacy, autonomy, and the commodification of genetic profiles for profit. We’ve entered an era where biometric identity is currency.

TTAM will acquire substantially all of 23andMe’s assets for $305 million, including its Personal Genome Service and Research ...

Regeneron is a large pharmaceutical company with a market cap of more than $60 billion; its acquisition of 23andMe could unlock some attractive growth opportunities over the long haul. Image ...

Me’s sale to Regeneron is not yet a done deal. The privacy ombudsman is scheduled to report on the privacy aspects of the sale by mid-June.